Broker-Dealer AgreementBroker-Dealer Agreement • July 19th, 2022 • Balanced Pharma Inc • Pharmaceutical preparations
This agreement (together with exhibits and schedules, the “Agreement”) is entered into by and between Balanced Pharma Incorporated (“Client”), a Delaware Corporation, and Dalmore Group, LLC., a New York Limited Liability Company (“Dalmore”). Client and Dalmore agree to be bound by the terms of this Agreement, effective as of April 1, 2022 (the “Effective Date”):
ADDENDUM TO BROKER/DEALER AGREEMENTBroker/Dealer Agreement • July 19th, 2022 • Balanced Pharma Inc • Pharmaceutical preparations
This is an addendum to the broker/dealer agreement (“Addendum”) between Dalmore Group, LLC and Balanced Pharma, Inc. (“Issuer Name” or “Client”) dated April 1, 2022. This Addendum is effective as of July 13, 2022. This Addendum will update Section 3 (“Compensation”) of the original Agreement. Specifically, as compensation for the Services, Client shall pay to Dalmore a fee equal to one percent (1%) on the aggregate of amounts raised as a result of investors that initiated their investment not referred by Dalmore and an additional five percent (5%) on the aggregate amount raised as a result of investors that initiated their investment through a referral from Justly.
